Child Birth In Space, Sniffing Out Malaria, Kepler Calls It Quits

Child Birth In Space, Sniffing Out Malaria, Kepler Calls It Quits
There should be no boundaries to human endeavor, said renowned physicist Stephen Hawking, and biotech company SpaceLife Origin is taking its cue from this quote. In this week’s “Did you know?” column, we are presenting news about SpaceLife Origin’s bold initiatives to colonize other planets, results of the world’s first study into dog’s ability to detect malaria, and NASA retiring... Read More

Puma Biotechnology’s stock plunges to pace premarket losers after key drug Nerlynx disappoints

Puma Biotechnology’s stock plunges to pace premarket losers after key drug Nerlynx disappoints
Shares of Puma Biotechnology Inc. PBYI, +4.18% plummeted 38% toward a 2 1/2-year low, to pace all premarket decliners, after the company reported third-quarter earnings and revenue that beat expectations, but reported disappointing results of its key product, the breast cancer treatment Nerlynx. That prompted J.P. Morgan to swing to bearish from bullish and slash its stock price target. Total... Read More

Stocks Move Sharply Higher On Optimism About Trade Talks – U.S. Commentary

Stocks Move Sharply Higher On Optimism About Trade Talks – U.S. Commentary
After initially showing a lack of direction, stocks moved sharply higher over the course of the trading session on Thursday. With the gains on the day, the major averages extended the strong upward move seen over the two previous sessions. The major averages ended the day just off their highs of the session. The Dow surged up 264.98 points or... Read More

Orchard Therapeutics prices IPO at $14 per ADS

Orchard Therapeutics prices IPO at $14 per ADS
Orchard Therapeutics PLC ORTX, +0.00% priced its initial public offering at $14 per American Depositary Share. The biotech that specializes in ex vivo gene therapies sold 14.3 million shares to raise $200.2 million. Shares will start trading later Wednesday on Nasdaq under the ticker symbol “ORTX”. JPMorgan, Goldman Sachs and Cowen were lead underwriters on the deal with Wedbush acting... Read More

IRWD On Watch, Eagle Hurt As Study Fails, NCNA Down Over 30% This Month

IRWD On Watch, Eagle Hurt As Study Fails, NCNA Down Over 30% This Month
The following are some of the pharma/biotech stocks that posted the biggest percentage decline today. 1. vTv Therapeutics Inc. (VTVT) Lost 18.97% to close Tuesday’s (Oct.30) trading at $2.35. News: The Company’s securities were transferred from the Nasdaq Global Market to the Nasdaq Capital Market at the opening of business on October 30, 2018. There are three tiers of Nasdaq... Read More

DXR Heartened By New Data, APVO Braces For Busy Months, AMED In Good Health

DXR Heartened By New Data, APVO Braces For Busy Months, AMED In Good Health
The following are some of today’s top gainers in the pharma/biotech sector. 1. Daxor Corporation (DXR) Gained 86.84% to close Tuesday’s (Oct.30) trading at $8.80. News: New data published in the Journal of the American College of Cardiology – Heart Failure shows a reduction of 82% mortality and 56% reduced 30-day readmission rehospitalization in patients who received individualized treatment for... Read More

CSBR Down 19% In 4 Days, TLRY & Pot Stocks Losing Steam, MLNT On Watch

CSBR Down 19% In 4 Days, TLRY & Pot Stocks Losing Steam, MLNT On Watch
The following are some of the pharma/biotech stocks that posted the biggest percentage decline today. 1. Champions Oncology Inc. (CSBR) Champions Oncology is engaged in the development and sale of advanced technology solutions and products to personalize the development and use of oncology drugs. Lost 17.93% to close Monday’s (Oct.29) trading at $9.84. News: No news Recent event: On September... Read More

CASI Turning Heads, GEN On Watch, MRKR For The Long Haul

CASI Turning Heads, GEN On Watch, MRKR For The Long Haul
The following are some of today’s top gainers in the pharma/biotech sector. 1. LogicBio Therapeutics Inc. (LOGC) LogicBio is a genome editing company focused on developing medicines for rare diseases. Gained 25.06% to close Monday’s (Oct.29) trading at $10.73. News: No news Recent events: — The Company went public on the Nasdaq Global Market on October 19, 2018, offering its... Read More